Literature DB >> 7859199

Adverse reaction to mefloquine associated with ethanol ingestion.

R C Wittes1, R Saginur.   

Abstract

A 40-year-old man with no history of neuropsychiatric illness was taking one 250-mg tablet of mefloquine (MFQ) weekly for malaria prophylaxis while in Tanzania. He experienced no adverse reaction in association with his first two doses. Concurrently with both his third and his fourth dose he consumed about half a litre of whisky. On both occasions he experienced hallucinations, paranoid delusions and suicidal ideation. Thereafter he continued taking the MFQ, abstained completely from ethanol ingestion and had no recurrence of psychiatric symptoms. It is hypothesized that the combination of MFQ and ethanol caused the two episodes of severe psychiatric disturbance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7859199      PMCID: PMC1337705     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  9 in total

1.  Neuropsychiatric side effects after the use of mefloquine.

Authors:  T Weinke; M Trautmann; T Held; G Weber; D Eichenlaub; K Fleischer; W Kern; H D Pohle
Journal:  Am J Trop Med Hyg       Date:  1991-07       Impact factor: 2.345

2.  Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions.

Authors:  J L Bem; L Kerr; D Stuerchler
Journal:  J Trop Med Hyg       Date:  1992-06

3.  Acute psychosis after mefloquine.

Authors:  P C Stuiver; R J Ligthelm; T J Goud
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

4.  Neuropsychiatric side effects of mefloquine.

Authors:  D Stürchler; J Handschin; D Kaiser; L Kerr; M L Mittelholzer; R Reber; M Fernex
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

5.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

6.  Neurologic reactions after a therapeutic dose of mefloquine.

Authors:  L C Patchen; C C Campbell; S B Williams
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

7.  Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy.

Authors:  R Steffen; R Heusser; R Mächler; R Bruppacher; U Naef; D Chen; A M Hofmann; B Somaini
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

8.  Tolerability of prophylactic Lariam regimens.

Authors:  E Boudreau; B Schuster; J Sanchez; W Novakowski; R Johnson; D Redmond; R Hanson; L Dausel
Journal:  Trop Med Parasitol       Date:  1993-09

Review 9.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

  9 in total
  9 in total

1.  Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

Review 2.  Pharmacokinetic interactions between alcohol and other drugs.

Authors:  A G Fraser
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 3.  A week in the life of a travel clinic.

Authors:  D C Blair
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials.

Authors:  Christoph R Meier; Karen Wilcock; Susan S Jick
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine.

Authors:  Alan L Peterson; Robert A Seegmiller; Libby S Schindler
Journal:  Case Rep Psychiatry       Date:  2011-09-08

Review 6.  The position of mefloquine as a 21st century malaria chemoprophylaxis.

Authors:  Patricia Schlagenhauf; Miriam Adamcova; Loredana Regep; Martin T Schaerer; Hans-Georg Rhein
Journal:  Malar J       Date:  2010-12-09       Impact factor: 2.979

7.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

8.  Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine.

Authors:  Jeffrey Livezey; Thomas Oliver; Louis Cantilena
Journal:  Drug Saf Case Rep       Date:  2016-12

9.  Behavioral effects of mefloquine in tail suspension and light/dark tests.

Authors:  John Michael Holden; Richard Slivicki; Rachel Dahl; Xia Dong; Matt Dwyer; Weston Holley; Crissa Knott
Journal:  Springerplus       Date:  2015-11-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.